Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

COUCH Medcomms

- PMLiVE

Stronger Together: Medscape Education Celebrates Accomplishments in Rare Disease and Anticipates the World Health Assembly Adoption of the Resolution on Rare Diseases

Medscape Education is proud to be showcasing the power of working together in rare disease education and advocacy by co-hosting a side event at the 78th World Health Assembly in...

Medscape Education

- PMLiVE

AbbVie and ADARx enter multi-billion dollar partnership to develop siRNA therapies

The companies will focus on developing therapeutics across neuroscience, immunology and oncology

- PMLiVE

Sanofi unveils $20bn US investment to boost R&D and manufacturing presence

The company is the latest major drugmaker to announce a significant investment in the country

- PMLiVE

MSD receives MHRA approval for adult-specific pneumococcal vaccine Capvaxive

Illnesses caused by Streptococcus pneumoniae are currently considered a major public health problem by WHO

- PMLiVE

Novo Nordisk and Septerna enter $2.2bn cardiometabolic disease partnership

The companies will launch four development programmes for potential small molecule therapies

- PMLiVE

Eli Lilly to expand long-standing Purdue University partnership with $250m investment

The alliance will aim to bring medicines to patients faster using advanced technologies

- PMLiVE

AbbVie’s Emrelis granted FDA accelerated approval to treat advanced lung cancer

An estimated 226,650 people will be diagnosed with lung cancer in the US this year

- PMLiVE

Why Health Comms Teams Can’t Afford to Skip the Mid-Year Review

New McKinsey and Gartner data show that organisations who regularly reset strategy can outperform peers by up to 60%. In fast-moving health communications, the mid-year review is a crucial but...

Fox&Cat

- PMLiVE

GSK to acquire Boston’s liver disease candidate efimosfermin in deal worth up to $2bn

Steatotic liver disease affects approximately 5% of the global population

- PMLiVE

Cytokinetics shares positive phase 3 results for aficamten in heart disease

Up to one in 500 people in the UK and US are living with hypertrophic cardiomyopathy

- PMLiVE

Madrigal’s liver disease drug Rezdiffra shows promise in compensated MASH cirrhosis

The drug has already been approved in the US to treat patients with non-cirrhotic MASH

- PMLiVE

Roche’s Perjeta-based breast cancer regimen shows sustained survival benefits

Approximately 56,800 new breast cancer cases are diagnosed in the UK every year

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links